889MO - Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group

Background

Nodular lymphocytic predominance Hodgkin lymphoma (NLPHL) is a very unfrequent subtype of Hodgkin lymphoma, representing approximately 5% of all LH cases, with an incidence of 0.3 / 100,000 cases per year and with unique characteristics that distinguish it from classic Hodgkin lymphoma (HLc). Given its low frequency, it is very difficult to design randomized studies, being the accumulated experience of academic groups a source of relevant information for the management of these patients.

Methods

85 patients recruited by the Spanish Lymphoma Group of 12 hospitals have been retrospectively analysed describing their clinical and sociodemographic characteristics.

Results

The median follow-up was 16 years, with a 10-year OS of 92.9% and 81.2% at 20 years. 5 patients developed a second tumor. There is no transformation to more aggressive lymphoma. There was a 31% relapse, being 77% a single and supradiaphragmatic relapse. The percentage of progression to first-line treatment was: 50% in those under observation, 26% of those who received QT-RT, 27% of those who received only RT, and 47% of those who received CH exclusively. The mean time to relapse was 3 years and 47% presented relapses beyond 5 years (higher probability in stages IV p <0.001). Table: 889MO

Conclusions

This is one of the longest follow-ups of NLPHL published confirming its excellent prognosis. Treatment could be adapted to exclusive RT when possible in the initial stages.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.